Sirio Pharma Co., Ltd.

SZSE:300791 Stock Report

Market Cap: CN¥6.7b

Sirio Pharma Future Growth

Future criteria checks 3/6

Sirio Pharma is forecast to grow earnings and revenue by 21.1% and 14.4% per annum respectively. EPS is expected to grow by 20.8% per annum. Return on equity is forecast to be 16.8% in 3 years.

Key information

21.1%

Earnings growth rate

20.8%

EPS growth rate

Personal Products earnings growth25.8%
Revenue growth rate14.4%
Future return on equity16.8%
Analyst coverage

Good

Last updated30 Oct 2024

Recent future growth updates

Recent updates

When Should You Buy Sirio Pharma Co., Ltd. (SZSE:300791)?

Dec 13
When Should You Buy Sirio Pharma Co., Ltd. (SZSE:300791)?

Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?

Oct 14
Is Now The Time To Put Sirio Pharma (SZSE:300791) On Your Watchlist?

The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Sep 30
The Market Lifts Sirio Pharma Co., Ltd. (SZSE:300791) Shares 27% But It Can Do More

Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Sep 23
Is Sirio Pharma (SZSE:300791) Using Too Much Debt?

Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Aug 01
Sirio Pharma Co., Ltd.'s (SZSE:300791) Prospects Need A Boost To Lift Shares

Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Jun 30
Sirio Pharma (SZSE:300791) Will Be Hoping To Turn Its Returns On Capital Around

Is Sirio Pharma (SZSE:300791) A Risky Investment?

Jun 12
Is Sirio Pharma (SZSE:300791) A Risky Investment?

An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Apr 24
An Intrinsic Calculation For Sirio Pharma Co., Ltd. (SZSE:300791) Suggests It's 24% Undervalued

Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Mar 06
Sirio Pharma (SZSE:300791) Seems To Use Debt Quite Sensibly

Earnings and Revenue Growth Forecasts

SZSE:300791 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,6825403168135
12/31/20255,0004541426446
12/31/20244,32536615406
9/30/20244,128336-24376N/A
6/30/20244,028334-82361N/A
3/31/20243,831315-155276N/A
12/31/20233,582281-66386N/A
9/30/20233,22222113393N/A
6/30/20232,94120464370N/A
3/31/20232,78822734344N/A
1/1/20232,507212151445N/A
9/30/20222,40920812388N/A
6/30/20222,315196-74397N/A
3/31/20222,283189-72461N/A
12/31/20212,369232-183341N/A
9/30/20212,361272-96384N/A
6/30/20212,316279-32367N/A
3/31/20212,216265-52257N/A
12/31/20202,06725796320N/A
9/30/20201,86520985272N/A
6/30/20201,71017840203N/A
3/31/20201,55415645206N/A
12/31/20191,58014365232N/A
9/30/20191,62518679236N/A
12/31/20181,595203-56183N/A
12/31/20171,330104N/A49N/A
12/31/2016786704N/A-98N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300791's forecast earnings growth (21.1% per year) is above the savings rate (2.8%).

Earnings vs Market: 300791's earnings (21.1% per year) are forecast to grow slower than the CN market (25.7% per year).

High Growth Earnings: 300791's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300791's revenue (14.4% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 300791's revenue (14.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300791's Return on Equity is forecast to be low in 3 years time (16.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 08:31
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sirio Pharma Co., Ltd. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jing HuangChasing Securities
Wenbo ChenChina International Capital Corporation Limited
Wendan WangChina International Capital Corporation Limited